Structural evolution of p53, p63, and p73: Implication for heterotetramer formation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 42, 2009, Pages 17705-17710

  Joerger, Andreas C ^a   Rajagopalan, Sridharan ^a   Natan, Eviatar ^a   Veprintsev, Dmitry B ^b   Robinson, Carol V ^c   Fersht, Alan R ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Crystallography; Mass spectrometry; Tetramer; Transcription factor

Indexed keywords

DIMER; PROTEIN P53; PROTEIN P63; PROTEIN P73; TETRAMER;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; INTROSPECTION; MASS SPECTROMETRY; MOLECULAR EVOLUTION; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN STRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; CRYSTALLOGRAPHY, X-RAY; DNA-BINDING PROTEINS; EVOLUTION, MOLECULAR; GENETIC VARIATION; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROTEIN STRUCTURE, QUATERNARY; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THERMODYNAMICS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 70449588702     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0905867106     Document Type: Article

References (34)

1. Pietsch EC, Sykes SM, McMahon SB, Murphy ME (2008) The p53 family and programmed cell death. Oncogene 27:6507-6521.
2. Yang A, Kaghad M, Caput D, McKeon F (2002) On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 18:90-95. (Pubitemid 34127808)
3. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307-310.
4. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8:275-283.
5. Joerger AC, Fersht AR (2007) Structure-function-rescue: The diverse nature of common p53 cancer mutants. Oncogene 26:2226-2242.
6. Petitjean A, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629. (Pubitemid 46744292)
7. Yang A, et al. (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2:305-316. (Pubitemid 128379271)
8. Kaghad M, et al. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819. (Pubitemid 27357971)
9. Mills AA, et al. (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398:708-713.
10. Yang A, et al. (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404:99-103. (Pubitemid 30143141)
11. Suh EK, et al. (2006) p63 protects the female germ line during meiotic arrest. Nature 444:624-628.
12. Itahana Y, Ke H, Zhang Y (2009) p53 Oligomerization is essential for its C-terminal lysine acetylation. J Biol Chem 284:5158-5164.
13. Kitayner M, et al. (2006) Structural basis of DNA recognition by p53 tetramers. Mol Cell 22:741-753. (Pubitemid 43912472)
14. Tidow H, et al. (2007) Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc Natl Acad Sci USA 104:12324-12329. (Pubitemid 47206136)
15. Scoumanne A, Harms KL, Chen X (2005) Structural basis for gene activation by p53 family members. Cancer Biol Ther 4:1178-1185.
16. Murray-Zmijewski F, Lane DP, Bourdon JC (2006) p53/p63/p73 isoforms: An orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 13:962-972. (Pubitemid 43753487)
17. Joerger AC, Fersht AR (2008) Structural biology of the tumor suppressor p53. Annu Rev Biochem 77:557-582.
18. Mittl PR, Chene P, Grutter MG (1998) Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template. Acta Crystallogr D 54:86-89. (Pubitemid 28111121)
19. Jeffrey PD, Gorina S, Pavletich NP (1995) Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267:1498-1502.
20. Clore GM, et al. (1995) Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat Struct Biol 2:321-333.
21. Lee W, et al. (1994) Solution structure of the tetramericminimumtransforming domain of p53. Nat Struct Biol 1:877-890. (Pubitemid 24974811)
22. Ou HD, Lohr F, Vogel V, Mantele W, Dotsch V (2007) Structural evolution of C-terminal domains in the p53 family. EMBO J 3463-3473. (Pubitemid 47123529)
23. Davison TS, et al. (1999) p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J Biol Chem 274:18709-18714. (Pubitemid 129519278)
24. Mateu MG, Fersht AR (1999) Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired heterooligomerization. Proc Natl Acad Sci USA 96:3595-3599.
25. DiGiammarino EL, et al. (2002) A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 9:12-16.
26. Petitjean A, Hainaut P, Caron de Fromentel C (2006) TP63 gene in stress response and carcinogenesis: A broader role than expected. Bull Cancer 93:E126-135.
27. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C (2001) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21:1874-1887. (Pubitemid 32156407)
28. Strano S, et al. (2002) Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277:18817-18826. (Pubitemid 34952441)
29. Kravchenko JE, et al. (2008) Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 105:6302-6307.
30. Natan E, Hirschberg D, Morgner N, Robinson CV, Fersht AR (2009) Ultraslow oligomerization equilibria of p53 and its implications. Proc Natl Acad Sci USA 106:14327-14332.
31. Li Y, Prives C (2007) Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 26:2220-2225. (Pubitemid 46536648)
32. Petitjean A, et al. (2008) Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73. Carcinogenesis 29:273-281. (Pubitemid 351359665)
33. Hernandez H, Robinson CV (2007) Determining the stoichiometry and interactions of macromolecular assemblies from mass spectrometry. Nat Protocols 2:715-726. (Pubitemid 47040033)
34. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ (2009) Jalview Version 2 - A multiple sequence alignment editor and analysis workbench. Bioinformatics 25:1189-1191.